COMPARE · Data as of August 24, 2026
AZN vs TAK
Verdict: Side-by-side breakdown using the Bull Rankings model. AZN scored 74.5, TAK scored 60.0 — AZN leads.
Compare another set
Different reporting periods. AZN's fundamentals are as of December 2025, but TAK's are as of March 2025 — a 9-month gap. Growth, margin and valuation figures below therefore describe different windows and aren't strictly like-for-like.
AZN
AstraZeneca PLC
74.5
$166.71 · $258.5B
fundamentals as of
Score gap
14.5
AZN leads
TAK
Takeda Pharmaceutical Company Limited
60
$18.24 · $58.2B
fundamentals as of
At a glance · who leads each dimension, on the model's own rules
- Fastest growthAZN+8.6%
- Strongest balance sheetAZN0.64
- Highest qualityAZN78 / 100
Side by side · every name on one set of axes
The model, pillar by pillar (0–100 each)
AZN
stronger →← stronger
TAK
78
Qualityreturns · margins · balance sheet
49
78
Growthrevenue & earnings expansion
60
68
Valuevaluation vs sector peers
87
AZN is stronger on 2 of 3 pillars.
Fundamentals, head-to-head
AZN
TAK
$11.8bA-
FCF
$3.1bB
+8.6%B
Rev
+7.5%B
0.64C+
D/E
0.73C+
24.9xB
P/E
—
1.43B
PEG
0.41A
—
P/S
2.0xB+
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
Valuation · DCF cross-check
AZN
TAK
20% above
Price vs fair valuelower is cheaper
17% above
~13%/yr
Growth the price implies10-yr FCF · lower = less priced in
~9%/yr
-27%
1-yr DCF upside
-19%
-17%
5-yr DCF upside
-15%
+0%
10-yr DCF upside
-7%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
AZN
Why this score
- Raising its dividend
TAK
Why this score
- Foreign reporter (JPY)
The companies
AZNAstraZeneca PLC
Why now
Drug Manufacturers - General · market cap $258.5b. Down 22% from 52-week high of $212.71 — deep drawdown territory. 10 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $213.99 (implying +28% upside).
Moat
Net margin 17% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 21% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 115% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
TAKTakeda Pharmaceutical Company Limited
Why now
Drug Manufacturers - Specialty & Generic · market cap $58.2b. 3% off the 52-week high of $18.90. PEG 0.41 — paying under fair value for the growth rate. 3 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $21.98 (implying +21% upside).
Moat
$58.2b market cap gives the company enough scale to absorb fixed costs that subscale competitors can't, without yet being so large that growth has to come from acquisition. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Net margin 2.4% is thin — operating leverage cuts both ways; input-cost inflation or pricing pressure hits the bottom line first. ROE 2% is below the long-run sustainable threshold of ~10% — capital efficiency would need to improve for the equity base to compound at the market rate. Patent cliff exposure — a single approved molecule can carry the company; when patent protection expires, generic / biosimilar competition can erase 80% of the revenue in 2-3 years.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where AZN and TAK diverge
On the headline score the gap is 14.5 points in favor of AZN. They get there differently, though — each leads on a different pillar, so the better pick depends on which you weight.
- QualityAZN 78.1 · TAK 48.6AZN +29.5
- ValueAZN 67.5 · TAK 86.9TAK +19.4
- GrowthAZN 78.5 · TAK 59.7AZN +18.8
Pillars run 0–100 against sector peers, so a score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.